Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese HSK 1 – For Medical Students & Physicians A complete 20-lesson, 300-page Chinese HSK 1 course with a companion app in 21 languages — free forever. Arabic, Bengali, Dutch, English, Farsi, French, German, Hindi, Indonesian, Italian, Japanese, Korean, Portuguese, Russian, Spanish, Tagalog, Thai, Turkish, Ukrainian, Urdu, Vietnamese. By Bernd Sebastian Kamps and Andrea Melis

Diabetes

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 89 articles: HTML format

Single Articles

April 2026
1. NICHOLLS SJ, Pavo I, D'Alessio D
   Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes. Reply.
   N Engl J Med. 2026;394:10.
   PubMed    
   
   
   
2. ANKER MS, Butler J, Anker SD
   Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.
   N Engl J Med. 2026;394:1551-1553.
   PubMed    
   
   
   
3. XU H, Cong X, Lin L
   Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.
   N Engl J Med. 2026;394:1551.
   PubMed    
   
   
   
4. VAN BRUGGEN F
   Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.
   N Engl J Med. 2026;394:1551.
   PubMed    
   
   
   
5. BECATTINI C, Agnelli G, Paciaroni M
   Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.
   N Engl J Med. 2026;394:1550-1551.
   PubMed    
   
   
   
6. CHUAN F, Gao Y, Zhou B
   Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.
   N Engl J Med. 2026;394:1550.
   PubMed    
   
   
   
7. FANG M, Xu Y, Selvin E, Shin JI, et al
   Trends in Youth-Onset Type 2 Diabetes, 2013-2024.
   N Engl J Med. 2026;394:1451-1453.
   PubMed    
   
   
   
8. CHAN E, Lee G, Quach T, Doan TT, et al
   Tailoring Digital Diabetes Care for Culture and Language.
   N Engl J Med. 2026;394:1356-1358.
   PubMed    
   
   
   
9. ROSEN CJ, Ingelfinger JR
   GLP-1 Receptor Agonists.
   N Engl J Med. 2026;394:1313-1324.
   PubMed     Abstract available
   
   
   March 2026
10. KUKLA A, Hogan MC
    Finerenone for Diabetic Kidney Disease in Type 1 Diabetes - A Fine Answer?
    N Engl J Med. 2026;394:1019-1020.
    PubMed    
    
    
    
11. HEERSPINK HJL, Birkenfeld AL, Cherney DZI, Colhoun HM, et al
    Finerenone in Type 1 Diabetes and Chronic Kidney Disease.
    N Engl J Med. 2026;394:947-957.
    PubMed     Abstract available
    
    
    December 2025
12. NICHOLLS SJ, Pavo I, Bhatt DL, Buse JB, et al
    Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.
    N Engl J Med. 2025;393:2409-2420.
    PubMed     Abstract available
    
    
    
13. ROSENSTOCK J, Cox D, Denning M
    Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes. Reply.
    N Engl J Med. 2025;393:2277-2279.
    PubMed    
    
    
    
14. XIE X, Xuan X
    Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
    N Engl J Med. 2025;393:2276-2277.
    PubMed    
    
    
    
15. JAGARLAPUDI SP
    Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
    N Engl J Med. 2025;393:2276.
    PubMed    
    
    
    
16. NAGAOKA T
    Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
    N Engl J Med. 2025;393:2276.
    PubMed    
    
    
    November 2025
17. BOHULA EA, Marston NA, Bhatia AK, De Ferrari GM, et al
    Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.
    N Engl J Med. 2025 Nov 8. doi: 10.1056/NEJMoa2514428.
    PubMed     Abstract available
    
    
    October 2025
18. AGARWAL R, Rossing P, Mann JFE
    Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. Reply.
    N Engl J Med. 2025;393:1755.
    PubMed    
    
    
    
19. ROMAGNANI P, Soler MJ, Fervenza FC
    Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.
    N Engl J Med. 2025;393:1754.
    PubMed    
    
    
    
20. SILVER S
    Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.
    N Engl J Med. 2025;393:1754.
    PubMed    
    
    
    
21. ASSIL R, Hough A
    Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.
    N Engl J Med. 2025;393:1753-1754.
    PubMed    
    
    
    
22. ROSENSTOCK J, Carr MC, Child CJ
    Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes. Reply.
    N Engl J Med. 2025;393:1443-1444.
    PubMed    
    
    
    
23. SAMAJDAR SS, Joshi SR, Mukherjee S
    Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes.
    N Engl J Med. 2025;393:1442-1443.
    PubMed    
    
    
    
24. KHAN H, Adnan F
    Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes.
    N Engl J Med. 2025;393:1442.
    PubMed    
    
    
    September 2025
25. HEROLD KC, Pober JS
    Replacement of Beta Cells for Type 1 Diabetes.
    N Engl J Med. 2025;393:917-921.
    PubMed    
    
    
    
26. CARLSSON PO, Hu X, Scholz H, Ingvast S, et al
    Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression.
    N Engl J Med. 2025;393:887-894.
    PubMed     Abstract available
    
    
    August 2025
27. HALES CM
    Expanding the Treat-to-Target Toolbox for Obesity and Diabetes Care.
    N Engl J Med. 2025;393:712-714.
    PubMed    
    
    
    
28. KUDVA YC, Beck RW
    A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes. Reply.
    N Engl J Med. 2025;393:618-619.
    PubMed    
    
    
    
29. ZHANG F, Zhong Y
    A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes.
    N Engl J Med. 2025;393:618.
    PubMed    
    
    
    
30. SAXON D
    A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes.
    N Engl J Med. 2025;393:617-618.
    PubMed    
    
    
    
31. ZOCCALI C, Mallamaci F
    Combination Therapy for Chronic Kidney Disease and Type 2 Diabetes - A Promising Prelude.
    N Engl J Med. 2025;393:601-602.
    PubMed    
    
    
    July 2025
32. BI Y, Xu Y, Wang W
    Intensive Blood-Pressure Control in Patients with Type 2 Diabetes. Reply.
    N Engl J Med. 2025;393:97-98.
    PubMed    
    
    
    
33. GROSSMAN E, Messerli FH
    Intensive Blood-Pressure Control in Patients with Type 2 Diabetes.
    N Engl J Med. 2025;393:97.
    PubMed    
    
    
    
34. FERNANDEZ-FERNANDEZ B, Sarafidis P, Ortiz A
    Intensive Blood-Pressure Control in Patients with Type 2 Diabetes.
    N Engl J Med. 2025;393:96-97.
    PubMed    
    
    
    
35. JOLOBE OMP
    Intensive Blood-Pressure Control in Patients with Type 2 Diabetes.
    N Engl J Med. 2025;393:96.
    PubMed    
    
    
    
36. SCHMIEDER RE
    Intensive Blood-Pressure Control in Patients with Type 2 Diabetes.
    N Engl J Med. 2025;393:95-96.
    PubMed    
    
    
    June 2025
37. JASTREBOFF AM, Bunck MC, Ahmad NN
    Tirzepatide for Obesity Treatment and Diabetes Prevention. Reply.
    N Engl J Med. 2025;392:2492-2493.
    PubMed    
    
    
    
38. SHUKLA AK, Bhavya B
    Tirzepatide for Obesity Treatment and Diabetes Prevention.
    N Engl J Med. 2025;392:2492.
    PubMed    
    
    
    
39. BIRKENFELD AL, Bergman M, Stefan N
    Tirzepatide for Obesity Treatment and Diabetes Prevention.
    N Engl J Med. 2025;392:2491-2492.
    PubMed    
    
    
    
40. JASTREBOFF AM, Ryan DH, Bays HE, Ebeling PR, et al
    Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial.
    N Engl J Med. 2025 Jun 23. doi: 10.1056/NEJMoa2504214.
    PubMed     Abstract available
    
    
    
41. ROSENSTOCK J, Bailey T, Connery L, Miller E, et al
    Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy.
    N Engl J Med. 2025 Jun 22. doi: 10.1056/NEJMoa2502796.
    PubMed     Abstract available
    
    
    
42. INGELFINGER JR, Rosen CJ
    Weekly Insulins and Therapeutic Burden in Type 2 Diabetes.
    N Engl J Med. 2025 Jun 22. doi: 10.1056/NEJMe2508147.
    PubMed    
    
    
    
43. DAVIES MJ, Bajaj HS, Broholm C, Eliasen A, et al
    Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
    N Engl J Med. 2025 Jun 22. doi: 10.1056/NEJMoa2502082.
    PubMed     Abstract available
    
    
    
44. ROSENSTOCK J, Hsia S, Nevarez Ruiz L, Eyde S, et al
    Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
    N Engl J Med. 2025 Jun 21. doi: 10.1056/NEJMoa2505669.
    PubMed     Abstract available
    
    
    
45. REICHMAN TW, Markmann JF, Odorico J, Witkowski P, et al
    Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes.
    N Engl J Med. 2025 Jun 20. doi: 10.1056/NEJMoa2506549.
    PubMed     Abstract available
    
    
    
46. AGARWAL R, Green JB, Heerspink HJL, Mann JFE, et al
    Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.
    N Engl J Med. 2025 Jun 5. doi: 10.1056/NEJMoa2410659.
    PubMed     Abstract available
    
    
    
47. CHEUNG A, Quintos JBQ, Agarwal S
    Setting for Initial Education about Type 1 Diabetes.
    N Engl J Med. 2025;392:2164-2167.
    PubMed    
    
    
    May 2025
48. HATIPOGLU B
    Automated Insulin Pump in Type 2 Diabetes.
    N Engl J Med. 2025;392:1862-1863.
    PubMed    
    
    
    March 2025
49. MAGNUSSEN C, Alegre-Diaz J, Al-Nasser LA, Amouyel P, et al
    Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.
    N Engl J Med. 2025 Mar 30. doi: 10.1056/NEJMoa2415879.
    PubMed     Abstract available
    
    
    
50. MCGUIRE DK, Marx N, Mulvagh SL, Deanfield JE, et al
    Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.
    N Engl J Med. 2025 Mar 29. doi: 10.1056/NEJMoa2501006.
    PubMed     Abstract available
    
    
    
51. ANAND S, Beddhu S
    BPROAD - End of the Road for Debate on Systolic Blood-Pressure Goals in Type 2 Diabetes?
    N Engl J Med. 2025;392:1230-1232.
    PubMed    
    
    
    
52. KUDVA YC, Raghinaru D, Lum JW, Graham TE, et al
    A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes.
    N Engl J Med. 2025 Mar 19. doi: 10.1056/NEJMoa2415948.
    PubMed     Abstract available
    
    
    February 2025
53. LI S, Mikhael B, van Zyl DG
    Choice of Intravenous Fluid for Resuscitation in Diabetic Ketoacidosis.
    N Engl J Med. 2025;392:923-926.
    PubMed    
    
    
    November 2024
54. BI Y, Li M, Liu Y, Li T, et al
    Intensive Blood-Pressure Control in Patients with Type 2 Diabetes.
    N Engl J Med. 2024 Nov 16. doi: 10.1056/NEJMoa2412006.
    PubMed     Abstract available
    
    
    
55. RUBIN EJ, Leopold J, Morrissey S
    NEJM at AHA - Intensive Blood-Pressure Control in Patients with Type 2 Diabetes.
    N Engl J Med. 2024 Nov 16. doi: 10.1056/NEJMe2414476.
    PubMed    
    
    
    
56. JASTREBOFF AM, le Roux CW, Stefanski A, Aronne LJ, et al
    Tirzepatide for Obesity Treatment and Diabetes Prevention.
    N Engl J Med. 2024 Nov 13. doi: 10.1056/NEJMoa2410819.
    PubMed     Abstract available
    
    
    
57. PERKOVIC V, Tuttle KR, Pratley R
    Semaglutide for Chronic Kidney Disease in Type 2 Diabetes. Reply.
    N Engl J Med. 2024;391:1757.
    PubMed    
    
    
    
58. DA HORA PASSOS R, Narciso RC, da Silva AA
    Semaglutide for Chronic Kidney Disease in Type 2 Diabetes.
    N Engl J Med. 2024;391:1757.
    PubMed    
    
    
    October 2024
59. ISRAEL A, Vinker S, Merzon E
    More on Type 2 Diabetes in Patients with G6PD Deficiency. Reply.
    N Engl J Med. 2024;391:1664.
    PubMed    
    
    
    
60. CUI W
    More on Type 2 Diabetes in Patients with G6PD Deficiency.
    N Engl J Med. 2024;391:1664.
    PubMed    
    
    
    
61. HERRINGTON WG, Staplin N, Agrawal N, Wanner C, et al
    Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
    N Engl J Med. 2024 Oct 25. doi: 10.1056/NEJMoa2409183.
    PubMed     Abstract available
    
    
    September 2024
62. WYSHAM C, Bajaj HS, Del Prato S, Franco DR, et al
    Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment.
    N Engl J Med. 2024 Sep 10. doi: 10.1056/NEJMoa2403953.
    PubMed     Abstract available
    
    
    August 2024
63. PERSAD G, Dellgren JL, Emanuel EJ
    Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists. Reply.
    N Engl J Med. 2024;391:776.
    PubMed    
    
    
    
64. GONG JY, Shaw JE
    Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists.
    N Engl J Med. 2024;391:775-776.
    PubMed    
    
    
    
65. MENSAH MO, Freitas DJ, Cartwright JR
    Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists.
    N Engl J Med. 2024;391:775.
    PubMed    
    
    
    
66. MAKARY N, Razali Q
    Diabetes-Associated Scleredema.
    N Engl J Med. 2024;391:e15.
    PubMed    
    
    
    
67. ISRAEL A, Raz I, Vinker S, Magen E, et al
    Type 2 Diabetes in Patients with G6PD Deficiency.
    N Engl J Med. 2024;391:568-569.
    PubMed    
    
    
    July 2024
68. KOSIBOROD MN, Petrie MC, Borlaug BA
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes. Reply.
    N Engl J Med. 2024;391:381-382.
    PubMed    
    
    
    
69. AMMON JP, Jackson CD
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
    N Engl J Med. 2024;391:381.
    PubMed    
    
    
    
70. WAGNER J
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
    N Engl J Med. 2024;391:380-381.
    PubMed    
    
    
    
71. COHEN C, Cohen R, Sabouret P
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
    N Engl J Med. 2024;391:380.
    PubMed    
    
    
    
72. HERRINGTON WG, Haynes R
    Diabetic Kidney Disease - Semaglutide Flows into the Mainstream.
    N Engl J Med. 2024;391:178-179.
    PubMed    
    
    
    June 2024
73. MANRIQUE-ACEVEDO C, Hirsch IB, Eckel RH
    Prevention of Cardiovascular Disease in Type 1 Diabetes. Reply.
    N Engl J Med. 2024;390:2227.
    PubMed    
    
    
    
74. MAAHS DM, Svensson J
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:2226-2227.
    PubMed    
    
    
    
75. WENSTEDT EFE, Vogt L
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:2226.
    PubMed    
    
    
    
76. CEFALU WT, Arreaza-Rubin G
    Engineering an Insulin Complex to Treat Diabetes.
    N Engl J Med. 2024;390:2214-2216.
    PubMed    
    
    
    
77. ROY N, Mandal M
    Insulin-Induced Lipohypertrophy.
    N Engl J Med. 2024;390:e60.
    PubMed    
    
    
    May 2024
78. BICHET DG, Bockenhauer D
    Thirst, Hunger, and Nephrogenic Diabetes Insipidus.
    N Engl J Med. 2024;390:1922-1924.
    PubMed    
    
    
    
79. EMANUEL EJ, Dellgren JL, McCoy MS, Persad G, et al
    Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists.
    N Engl J Med. 2024;390:1839-1842.
    PubMed    
    
    
    
80. PERKOVIC V, Tuttle KR, Rossing P, Mahaffey KW, et al
    Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
    N Engl J Med. 2024 May 24. doi: 10.1056/NEJMoa2403347.
    PubMed     Abstract available
    
    
    April 2024
81. KOSIBOROD MN, Petrie MC, Borlaug BA, Butler J, et al
    Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
    N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMoa2313917.
    PubMed     Abstract available
    
    
    
82. BUTLER J, Jones WS, Udell JA, Anker SD, et al
    Empagliflozin after Acute Myocardial Infarction.
    N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMoa2314051.
    PubMed     Abstract available
    
    
    
83. MANRIQUE-ACEVEDO C, Hirsch IB, Eckel RH
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:1207-1217.
    PubMed    
    
    
    
84. VAZQUEZ MA, Oliver G, Amarasingham R, Sundaram V, et al
    Pragmatic Trial of Hospitalization Rate in Chronic Kidney Disease.
    N Engl J Med. 2024;390:1196-1206.
    PubMed     Abstract available
    
    
    
85. FOURMAN LT, Tsai LL, Brown RJ, O'Rahilly S, et al
    Case 10-2024: A 46-Year-Old Woman with Hyperglycemia Refractory to Insulin Therapy.
    N Engl J Med. 2024;390:1219-1229.
    PubMed    
    
    
    March 2024
86. HUGHES MS, Addala A, Buckingham B
    Digital Technology for Diabetes. Reply.
    N Engl J Med. 2024;390:963-964.
    PubMed    
    
    
    
87. BERG TJ
    Digital Technology for Diabetes.
    N Engl J Med. 2024;390:963.
    PubMed    
    
    
    
88. TUMMINIA A, Gullo D, Frasca F
    Digital Technology for Diabetes.
    N Engl J Med. 2024;390:962-963.
    PubMed    
    
    
    
89. KINNY-KOSTER B, Michalski CW, Loos M
    Digital Technology for Diabetes.
    N Engl J Med. 2024;390:962.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum